Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

SAB Biotherapeutics (SABS) Return on Capital Employed (2021 - 2025)

Historic Return on Capital Employed for SAB Biotherapeutics (SABS) over the last 5 years, with Q3 2025 value amounting to 0.45%.

  • SAB Biotherapeutics' Return on Capital Employed rose 6100.0% to 0.45% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.45%, marking a year-over-year increase of 6100.0%. This contributed to the annual value of 0.77% for FY2024, which is 900.0% down from last year.
  • Per SAB Biotherapeutics' latest filing, its Return on Capital Employed stood at 0.45% for Q3 2025, which was up 6100.0% from 1.78% recorded in Q2 2025.
  • SAB Biotherapeutics' Return on Capital Employed's 5-year high stood at 0.18% during Q4 2021, with a 5-year trough of 1.78% in Q2 2025.
  • Its 5-year average for Return on Capital Employed is 0.85%, with a median of 0.81% in 2023.
  • Examining YoY changes over the last 5 years, SAB Biotherapeutics' Return on Capital Employed showed a top increase of 6100bps in 2025 and a maximum decrease of -10100bps in 2025.
  • Over the past 5 years, SAB Biotherapeutics' Return on Capital Employed (Quarter) stood at 0.18% in 2021, then tumbled by -327bps to 0.79% in 2022, then dropped by -7bps to 0.84% in 2023, then dropped by -25bps to 1.05% in 2024, then surged by 57bps to 0.45% in 2025.
  • Its last three reported values are 0.45% in Q3 2025, 1.78% for Q2 2025, and 1.34% during Q1 2025.